-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 10, 2025

Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support services for these patients.

Episodes in this series

EP. 1 Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP. 1 Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP. 2 Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP. 2 Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP. 3 Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

EP. 3 Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

EP. 4 Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

EP. 4 Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

EP. 5 Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

EP. 5 Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

Video content above is prompted by the following:

How do you assess the individual support needs of each patient when they are diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)?
In a perfect world, describe what industry-provided support services look like for patients diagnosed with DLBCL and FL.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression

ByNadege Gunn, MD

July 10th 2026

Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World

ByNadege Gunn, MD

July 10th 2026

Experts featured in this series.

Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?